BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 30791455)

  • 1. Protein Phosphatases-A Touchy Enemy in the Battle Against Glioblastomas: A Review.
    Tomiyama A; Kobayashi T; Mori K; Ichimura K
    Cancers (Basel); 2019 Feb; 11(2):. PubMed ID: 30791455
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Gonçalves CS; Vieira de Castro J; Pojo M; Martins EP; Queirós S; Chautard E; Taipa R; Pires MM; Pinto AA; Pardal F; Custódia C; Faria CC; Clara C; Reis RM; Sousa N; Costa BM
    Theranostics; 2018; 8(17):4805-4823. PubMed ID: 30279739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sprouty2 Drives Drug Resistance and Proliferation in Glioblastoma.
    Walsh AM; Kapoor GS; Buonato JM; Mathew LK; Bi Y; Davuluri RV; Martinez-Lage M; Simon MC; O'Rourke DM; Lazzara MJ
    Mol Cancer Res; 2015 Aug; 13(8):1227-37. PubMed ID: 25934697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PTP4A3 is a target for inhibition of cell proliferatin, migration and invasion through Akt/mTOR signaling pathway in glioblastoma under the regulation of miR-137.
    Wang L; Liu J; Zhong Z; Gong X; Liu W; Shi L; Li X
    Brain Res; 2016 Sep; 1646():441-450. PubMed ID: 27328425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polycomb complex mediated epigenetic reprogramming alters TGF-β signaling via a novel EZH2/miR-490/TGIF2 axis thereby inducing migration and EMT potential in glioblastomas.
    Vinchure OS; Sharma V; Tabasum S; Ghosh S; Singh RP; Sarkar C; Kulshreshtha R
    Int J Cancer; 2019 Sep; 145(5):1254-1269. PubMed ID: 31008529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration.
    Clark PA; Bhattacharya S; Elmayan A; Darjatmoko SR; Thuro BA; Yan MB; van Ginkel PR; Polans AS; Kuo JS
    J Neurosurg; 2017 May; 126(5):1448-1460. PubMed ID: 27419830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioinformatic analyses reveal a distinct Notch activation induced by STAT3 phosphorylation in the mesenchymal subtype of glioblastoma.
    Cheng W; Zhang C; Ren X; Jiang Y; Han S; Liu Y; Cai J; Li M; Wang K; Liu Y; Hu H; Li Q; Yang P; Bao Z; Wu A
    J Neurosurg; 2017 Jan; 126(1):249-259. PubMed ID: 26967788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sox2, a stemness gene, regulates tumor-initiating and drug-resistant properties in CD133-positive glioblastoma stem cells.
    Song WS; Yang YP; Huang CS; Lu KH; Liu WH; Wu WW; Lee YY; Lo WL; Lee SD; Chen YW; Huang PI; Chen MT
    J Chin Med Assoc; 2016 Oct; 79(10):538-45. PubMed ID: 27530866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Signal transduction pathways and resistance to targeted therapies in glioma.
    Tomiyama A; Ichimura K
    Semin Cancer Biol; 2019 Oct; 58():118-129. PubMed ID: 30685341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New Directions in the Treatment of Glioblastoma.
    Reitman ZJ; Winkler F; Elia AEH
    Semin Neurol; 2018 Feb; 38(1):50-61. PubMed ID: 29548052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nuclear factor I A promotes temozolomide resistance in glioblastoma via activation of nuclear factor κB pathway.
    Yu X; Wang M; Zuo J; Wahafu A; Mao P; Li R; Wu W; Xie W; Wang J
    Life Sci; 2019 Nov; 236():116917. PubMed ID: 31614149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA‑543 inhibits proliferation, invasion and induces apoptosis of glioblastoma cells by directly targeting ADAM9.
    Ji T; Zhang X; Li W
    Mol Med Rep; 2017 Nov; 16(5):6419-6427. PubMed ID: 28849046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genome-wide expression profiling of glioblastoma using a large combined cohort.
    Tang J; He D; Yang P; He J; Zhang Y
    Sci Rep; 2018 Oct; 8(1):15104. PubMed ID: 30305647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of Kinase Signaling in Resistance to Bevacizumab Therapy for Glioblastoma Multiforme.
    Ramezani S; Vousooghi N; Joghataei MT; Chabok SY
    Cancer Biother Radiopharm; 2019 Aug; 34(6):345-354. PubMed ID: 31411929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy and Epigenetic Pathway Modulation in Glioblastoma Multiforme.
    Chin C; Lunking ES; de la Fuente M; Ayad NG
    Front Oncol; 2018; 8():521. PubMed ID: 30483476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFRvIII-Stat5 Signaling Enhances Glioblastoma Cell Migration and Survival.
    Roos A; Dhruv HD; Peng S; Inge LJ; Tuncali S; Pineda M; Millard N; Mayo Z; Eschbacher JM; Loftus JC; Winkles JA; Tran NL
    Mol Cancer Res; 2018 Jul; 16(7):1185-1195. PubMed ID: 29724813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FoxM1 Promotes Stemness and Radio-Resistance of Glioblastoma by Regulating the Master Stem Cell Regulator Sox2.
    Lee Y; Kim KH; Kim DG; Cho HJ; Kim Y; Rheey J; Shin K; Seo YJ; Choi YS; Lee JI; Lee J; Joo KM; Nam DH
    PLoS One; 2015; 10(10):e0137703. PubMed ID: 26444992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of WW domain proteins WWOX in development, prognosis, and treatment response of glioma.
    Liu SY; Chiang MF; Chen YJ
    Exp Biol Med (Maywood); 2015 Mar; 240(3):315-23. PubMed ID: 25432984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumour exosomes from cells harbouring PTPRZ1-MET fusion contribute to a malignant phenotype and temozolomide chemoresistance in glioblastoma.
    Zeng AL; Yan W; Liu YW; Wang Z; Hu Q; Nie E; Zhou X; Li R; Wang XF; Jiang T; You YP
    Oncogene; 2017 Sep; 36(38):5369-5381. PubMed ID: 28504721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coordination of signalling networks and tumorigenic properties by ABL in glioblastoma cells.
    Lamballe F; Toscano S; Conti F; Arechederra M; Baeza N; Figarella-Branger D; Helmbacher F; Maina F
    Oncotarget; 2016 Nov; 7(46):74747-74767. PubMed ID: 27732969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.